The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $85.09

Today's change-1.81 -2.08%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $85.09

Today's change-1.81 -2.08%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc down (U.S.)$1.81

Biomarin Pharmaceutical Inc closed sharply lower Tuesday, dropping (U.S.)$1.81 or 2.08% to (U.S.)$85.09. Over the last five days, shares have lost 4.08% and are down 18.78% for the last year to date. This security has underperformed the S&P 500 by 24.47% during the last year.

Key company metrics

  • Open(U.S.) $86.00
  • Previous close(U.S.) $86.90
  • High(U.S.) $87.41
  • Low(U.S.) $84.91
  • Bid / Ask(U.S.) $78.00 / (U.S.) $87.00
  • YTD % change-18.78%
  • Volume1,012,384
  • Average volume (10-day)1,781,375
  • Average volume (1-month)1,637,258
  • Average volume (3-month)1,782,095
  • 52-week range(U.S.) $62.12 to (U.S.) $151.75
  • Beta0.96
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.08
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX1.14%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue228209251203
Total other revenue--------
Total revenue228209251203
Gross profit185172211170
Total cost of revenue43374033
Total operating expense127291315269
Selling / general / administrative11493100100
Research & development176159158142
Depreciation / amortization8111
Interest expense (income), net operating--------
Unusual expense (income)-1710--0
Other operating expenses, total-441140
Operating income101-82-64-66
Interest income (expense), net non-operating-9-9-10-9
Gain (loss) on sale of assets--------
Other--------
Income before tax93-90-83-75
Income after tax69-91-82-68
Income tax, total240-1-7
Net income69-91-82-68
Total adjustments to net income--------
Net income before extra. items69-91-82-68
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items69-91-82-68
Inc. avail. to common incl. extra. items69-91-82-68
Diluted net income69-91-82-68
Dilution adjustment--------
Diluted weighted average shares161161160158
Diluted EPS excluding extraordinary itemsvalue per share0.43-0.57-0.51-0.43
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.26-0.57-0.51-0.43